STOCK TITAN

[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Supernus Pharmaceuticals (SUPN) announced it will report third quarter 2025 results after the market closes on November 4, 2025.

Management will host a conference call and webcast on November 4, 2025 at 4:30 p.m. ET to discuss its financial and business results.

The announcement was furnished via a press release included as Exhibit 99.1.

Supernus Pharmaceuticals (SUPN) ha annunciato che riferirà i risultati del terzo trimestre 2025 dopo la chiusura del mercato il 4 novembre 2025.

La direzione terrà una conference call e una trasmissione web il 4 novembre 2025 alle 16:30 ora dell'Est (ET) per discutere i suoi risultati finanziari e aziendali.

L'annuncio è stato fornito tramite un comunicato stampa incluso come Allegato 99.1.

Supernus Pharmaceuticals (SUPN) anunció que reportará los resultados del tercer trimestre de 2025 después del cierre del mercado el 4 de noviembre de 2025.

La dirección realizará una conferencia telefónica y una transmisión en webcast el 4 de noviembre de 2025 a las 4:30 p.m. hora del Este (ET) para discutir sus resultados financieros y comerciales.

El anuncio fue proporcionado mediante un comunicado de prensa incluido como el Anexo 99.1.

Supernus Pharmaceuticals (SUPN)는 2025년 11월 4일 장 마감 후 3분기 2025년 실적을 발표한다고 발표했습니다.

경영진은 2025년 11월 4일 동부표준시 오후 4시 30분에 재무 및 사업 실적을 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 주최할 예정입니다.

발표는 Exhibit 99.1에 포함된 보도자료를 통해 제공되었습니다.

Supernus Pharmaceuticals (SUPN) a annoncé qu'il publiera les résultats du troisième trimestre 2025 après la clôture du marché le 4 novembre 2025.

La direction organisera une conférence téléphonique et une diffusion en direct le 4 novembre 2025 à 16h30, heure de l'Est (ET), pour discuter de ses résultats financiers et commerciaux.

L'annonce a été fournie via un communiqué de presse inclus en tant qu'Exhibit 99.1.

Supernus Pharmaceuticals (SUPN) gab bekannt, dass es die Ergebnisse des dritten Quartals 2025 nach Börsenschluss am 4. November 2025 melden wird.

Die Geschäftsleitung wird am 4. November 2025 um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen und geschäftlichen Ergebnisse zu besprechen.

Die Ankündigung wurde über eine Pressemitteilung bereitgestellt, die als Exhibit 99.1 beigefügt ist.

Supernus Pharmaceuticals (SUPN) أعلنت أنها ستصدر نتائج الربع الثالث من عام 2025 بعد إغلاق السوق في 4 نوفمبر 2025.

ستعقد الإدارة مكالمة هاتفية وبثًا مباشرًا عبر الويب في 4 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة لمناقشة نتائجها المالية والتجارية.

تم تقديم الإعلان من خلال بيان صحفي مُدرج كـ Exhibit 99.1.

Supernus Pharmaceuticals (SUPN) 宣布将于2025年11月4日收市后披露2025年第三季度业绩。

管理层将在2025年11月4日美国东部时间下午4:30举行电话会议并进行网页直播,讨论公司的财务及业务业绩。

该公告通过作为 Exhibit 99.1 的新闻稿提供。

Positive
  • None.
Negative
  • None.

Supernus Pharmaceuticals (SUPN) ha annunciato che riferirà i risultati del terzo trimestre 2025 dopo la chiusura del mercato il 4 novembre 2025.

La direzione terrà una conference call e una trasmissione web il 4 novembre 2025 alle 16:30 ora dell'Est (ET) per discutere i suoi risultati finanziari e aziendali.

L'annuncio è stato fornito tramite un comunicato stampa incluso come Allegato 99.1.

Supernus Pharmaceuticals (SUPN) anunció que reportará los resultados del tercer trimestre de 2025 después del cierre del mercado el 4 de noviembre de 2025.

La dirección realizará una conferencia telefónica y una transmisión en webcast el 4 de noviembre de 2025 a las 4:30 p.m. hora del Este (ET) para discutir sus resultados financieros y comerciales.

El anuncio fue proporcionado mediante un comunicado de prensa incluido como el Anexo 99.1.

Supernus Pharmaceuticals (SUPN)는 2025년 11월 4일 장 마감 후 3분기 2025년 실적을 발표한다고 발표했습니다.

경영진은 2025년 11월 4일 동부표준시 오후 4시 30분에 재무 및 사업 실적을 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 주최할 예정입니다.

발표는 Exhibit 99.1에 포함된 보도자료를 통해 제공되었습니다.

Supernus Pharmaceuticals (SUPN) a annoncé qu'il publiera les résultats du troisième trimestre 2025 après la clôture du marché le 4 novembre 2025.

La direction organisera une conférence téléphonique et une diffusion en direct le 4 novembre 2025 à 16h30, heure de l'Est (ET), pour discuter de ses résultats financiers et commerciaux.

L'annonce a été fournie via un communiqué de presse inclus en tant qu'Exhibit 99.1.

Supernus Pharmaceuticals (SUPN) gab bekannt, dass es die Ergebnisse des dritten Quartals 2025 nach Börsenschluss am 4. November 2025 melden wird.

Die Geschäftsleitung wird am 4. November 2025 um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen und geschäftlichen Ergebnisse zu besprechen.

Die Ankündigung wurde über eine Pressemitteilung bereitgestellt, die als Exhibit 99.1 beigefügt ist.

false000135657600013565762025-10-212025-10-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): October 21, 2025
 
Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)
Delaware
001-3551820-2590184
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
9715 Key West Ave
Rockville
MD
20850
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number, including area code: (301) 838-2500
 
Not Applicable
(Former name or former address, if changed since last report.)

  Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per shareSUPNThe Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02 Results of Operations and Financial Condition.
On October 21, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter of 2025 after the market closes on Tuesday, November 4, 2025. The Company will host a conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. E.T. to discuss its third quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
ExhibitDescription
99.1
Press Release dated October 21, 2025 filed as an Exhibit pursuant to Item 2.02 hereof.
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
2


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 SUPERNUS PHARMACEUTICALS, INC.
  
DATED: October 21, 2025By:/s/ Timothy C. Dec
  Timothy C. Dec
Senior Vice President and Chief Financial Officer
3

FAQ

When will SUPN report Q3 2025 results?

The company will report third quarter 2025 results after the market closes on November 4, 2025.

What time is Supernus (SUPN) hosting its Q3 2025 call?

The conference call and webcast are scheduled for 4:30 p.m. ET on November 4, 2025.

What period does the upcoming SUPN announcement cover?

It covers the third quarter of 2025.

Will there be a webcast for SUPN’s Q3 2025 results?

Yes. The company will host a conference call and webcast on November 4, 2025 at 4:30 p.m. ET.

Where can I find the related SUPN press release?

It is furnished as Exhibit 99.1.
Supernus Pharma

NASDAQ:SUPN

SUPN Rankings

SUPN Latest News

SUPN Latest SEC Filings

SUPN Stock Data

2.89B
60.34M
4.23%
109.56%
8.56%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ROCKVILLE